Want to see FR:EQS full AI Analyst Report?
Top Page
Equasens
(EQS)
Select Model
Select Model
Rating:72Outperform
Price Target:
€37.00
▲(13.15% Upside)
Action:Reiterated
Date:09/29/26
The score is driven primarily by solid financial performance (durable profitability, healthy ROE, and a resilient balance sheet) and supportive valuation (low P/E with a strong dividend yield). These positives are tempered by weaker technicals (below key longer-term moving averages and negative MACD) and some recent fundamental soft spots (margin drift and declining free-cash-flow growth, plus data gaps that reduce clarity).
Positive Factors
Recurring healthcare software model
Recurring software, maintenance, and support revenues can create durable customer relationships and improve revenue visibility across reporting periods. Equasens also earns implementation and digital-service income, giving its pharmacy and healthcare technology platform multiple ways to deepen customer adoption.
Negative Factors
Margin compression
The decline in margins from the 2021–2023 period suggests that recent growth has been less profitable than earlier expansion. If this pressure persists, it could limit earnings growth, reduce funds available for innovation, and weaken the operating leverage expected from a software-focused business.
Read all positive and negative factors
Positive Factors
Negative Factors
Recurring healthcare software model
Recurring software, maintenance, and support revenues can create durable customer relationships and improve revenue visibility across reporting periods. Equasens also earns implementation and digital-service income, giving its pharmacy and healthcare technology platform multiple ways to deepen customer adoption.
Read all positive factors
Equasens (EQS) vs. iShares MSCI France ETF (EWQ)
Market Cap
€467.89M
Dividend Yield4.55%
Average Volume (3M)27.12K
Price to Earnings (P/E)11.4
Beta (1Y)0.45
Revenue Growth9.04%
EPS Growth13.05%
CountryFR
Employees1,462
SectorGeneral
Sector StrengthN/A
IndustrySoftware - Application
Share Statistics
EPS (TTM)2.59
Shares Outstanding15,174,125
10 Day Avg. Volume36,748
30 Day Avg. Volume27,119
Financial Highlights & Ratios
PEG Ratio1.16
Price to Book (P/B)2.68
Price to Sales (P/S)2.86
P/FCF Ratio14.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.94
Revenue Forecast (FY)€253.64M
Equasens Business Overview & Revenue Model
Company Description
Equasens S.A., established in 1996 and headquartered in Villers-les-Nancy, France, delivers a diverse portfolio of information technology solutions tailored for the European healthcare industry. The company primarily equips pharmacies and their ne...
How the Company Makes Money
Equasens primarily makes money by selling and supporting healthcare software used by pharmacies and other healthcare professionals. Its revenue model is mainly based on (1) recurring software revenues such as subscriptions, software licenses, and ...
Equasens Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
80
Positive
Cash Flow
73
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 236.52M | 216.75M | 219.79M | 214.07M | 193.07M |
| Gross Profit | 49.74M | 47.13M | 56.66M | 59.01M | 53.81M |
| EBITDA | 65.30M | 59.44M | 68.63M | 68.53M | 61.59M |
| Net Income | 39.33M | 36.23M | 47.05M | 46.25M | 39.12M |
Balance Sheet | |||||
| Total Assets | 439.00M | 398.01M | 394.05M | 350.81M | 329.95M |
| Cash, Cash Equivalents and Short-Term Investments | 87.10M | 40.16M | 54.69M | 68.01M | 64.79M |
| Total Debt | 53.80M | 48.45M | 69.27M | 66.52M | 84.06M |
| Total Liabilities | 176.00M | 157.32M | 166.42M | 154.01M | 164.72M |
| Stockholders Equity | 252.28M | 231.51M | 219.28M | 189.78M | 159.00M |
Cash Flow | |||||
| Free Cash Flow | 47.10M | 35.91M | 43.17M | 46.75M | 37.09M |
| Operating Cash Flow | 59.20M | 47.55M | 61.59M | 56.98M | 47.52M |
| Investing Cash Flow | -12.10M | -13.90M | -50.53M | -20.82M | -36.19M |
| Financing Cash Flow | -48.50M | -36.20M | -16.09M | -39.88M | -9.80M |
Equasens Technical Analysis
Neutral
32.70
Price Trends
32.66
Negative
33.87
Negative
35.60
Negative
Market Momentum
-0.61
Negative
47.94
Neutral
49.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EQS, the sentiment is Neutral. The current price of 32.7 is above the 20-day moving average (MA) of 31.12, above the 50-day MA of 32.66, and below the 200-day MA of 35.60, indicating a neutral trend. The MACD of -0.61 indicates Negative momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 49.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for FR:EQS.
Equasens Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | €467.89M | 11.39 | 16.36% | 4.55% | 9.04% | 13.05% | |
60 Neutral | €155.52M | -10.58 | -5.44% | 2.17% | -0.98% | ― | |
58 Neutral | €251.14M | 35.86 | 3.97% | ― | 6.28% | 204.56% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
42 Neutral | €181.09M | -3.26 | 90.10% | ― | 1.79% | 15.89% |
* General Sector Average
FR:EQS
Equasens
30.75
-7.48
-19.57%
FR:ALCGM
Cegedim
11.32
-0.38
-3.25%
FR:ALERS
Eurobio-Scientific SA
25.10
0.20
0.80%
FR:ALMDT
Median Technologies
3.75
0.50
15.38%
FR:ALBIO
Biosynex SA
0.87
0.18
25.94%
FR:ABLD
ABL Diagnostics SA
2.24
-2.07
-48.05%
Equasens Corporate Events
Equasens Files 2026 Half-Year Financial Report with AMF
Sep 29, 2026
Equasens announced that it has filed its 2026 half-year financial report with the French market regulator, the Autorité des Marchés Financiers, on 29 September 2026. The report, which includes the half-year activity review, consolidated ...
Equasens Delivers Higher H1 2026 Revenue and Margins on Acquisitions and Recurring Sales
Sep 28, 2026
Equasens reported first-half 2026 revenue of €124.5m, up 7.3%, driven mainly by the acquisition of Erevo and the integration of Novaprove and DIS, while like-for-like growth remained modest at 1.4%. Annual recurring revenue rose 8.8% to S...
Equasens Activates Business Continuity Plan After Fire at ASCA Site
Sep 22, 2026
Equasens has activated its business continuity plan after a fire destroyed the head office and storage site of its pharmacy electronic labelling subsidiary ASCA in Chessy, where 25 employees work and stocks for installations were held. Although th...
Equasens H1 2026 Revenue Rises on Recurring Digital Health Services
Jul 30, 2026
Equasens delivered a robust first half of 2026, increasing group revenue to €124.5m, up 7.3% year‑on‑year, with organic growth of 1.4% and annual recurring revenue reaching €111.1m, an 8.8% rise versus mid‑2025. The m...
Equasens Details H1 2026 Activity on New Share Liquidity Contract
Jul 28, 2026
Equasens has reported on the status of its liquidity contract following the appointment of NATIXIS ODDO BHF as new provider from 1 April 2026, replacing Gilbert Dupont. As of 30 June 2026, the liquidity account held 4,607 shares and EUR 314,173 in...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.